Gainers
Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Oct. 11.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased